Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression analysis of T-ALL cell lines TALL-1, RPMI-8402, SUPT11 and P12-ICHIKAWA after treatment with NVS-ZP7-3

ABSTRACT: Identification of a NVS-ZP7-3 response signature in T-ALL cell lines to understand the transcriptional response in both Notch pathway active cell lines and Notch pathway inactive lines.

ORGANISM(S): Homo sapiens

PROVIDER: GSE115690 | GEO | 2019/01/15

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Expression analysis of T-ALL cell lines TALL-1, RPMI-8402, SUPT11 and P12-ICHIKAWA after treatment with NVS-ZP7-3

Project description:Expression analysis of T-ALL cell lines TALL-1, RPMI-8402, SUPT11 and P12-ICHIKAWA after treatment with NVS-ZP7-3

| PRJNA475768 | ENA

TAL1 complex in human T-cell acute lymphoblastic leukemia (RPMI-8402)

Project description:The oncogenic transcription factor TAL1/SCL is aberrantly overexpressed in over 40% of cases of T-cell acute lymphoblastic leukemia (T-ALL), emphasizing the importance of the TAL1-regulated transcriptional program in the molecular pathogenesis of T-ALL. Here we identify regions occupied by TAL1 and its regulatory partners HEB, E2A, and GATA3 in a T-ALL cell line (RPMI-8402). Human T-ALL cells were cross-linked with formaldehyde for 20 min. DNA was enriched by chromatin immunoprecipitation (ChIP) and analyzed by Solexa sequencing. A sample of whole cell extract (WCE) was sequenced and used as the background to determine enrichment. ChIP was performed using an antibody against total TAL1 (Santa Cruz SC-12984), TCF12/HEB (Santa Cruz SC-357),TCF3/E2A (Santa Cruz SC-349X), and GATA3 (Santa Cruz SC-22206).

2012-07-09 | E-GEOD-39179 | biostudies-arrayexpress

TAL1 complex in human T-cell acute lymphoblastic leukemia (RPMI-8402)

2012-07-09 | GSE39179 | GEO

RNA-seq analysis in RPMI-8402 cells after knockout of MYC

Project description:RNA-seq analysis was performed in a RPMI-8402 T-ALL cell stably expressing Cas9 after knockout of MYC

2023-08-16 | GSE231960 | GEO

RNA-seq analysis in RPMI-8402 cells after knockout of MYCN

Project description:RNA-seq analysis was performed in a RPMI-8402 T-ALL cell stably expressing Cas9 after knockout of MYCN

2023-08-16 | GSE231959 | GEO

ATAC-seq analysis for Jurkat nd RPMI-8402 T-ALL cells

Project description:ATAC-seq analysis was performed in Jurkat and RPMI-8402 to analyze chromatin accessibility at steady state

2023-08-16 | GSE231955 | GEO

Pericyte-derived extracellular vesicle-mimetic nanovesicles ameliorates erectile dysfunction through Lipocalin 2 in the diabetic mice

Project description:Diabetes mellitus is one of the main causes of erectile dysfunction (ED). Due to neurovascular dysfunction, men with diabetic ED do not respond well to oral phosphodiesterase 5 inhibitors. Pericyte-derived extracellular vesicles-mimetic nanovesicles (PC-NVs) are known to play a role in promoting nerve regeneration in a mouse model of cavernous nerve injury. Here, we report that administration of PC-NVs can effectively promote penile angiogenesis and neural regeneration, thereby improving erectile function under diabetic conditions. We found that PC-NVs can induce endothelial proliferation, migration, and reduce cell apoptosis under diabetic conditions. In addition, PC-NVs induce neural regeneration in STZ-induced diabetic mice in vivo and ex vivo MPG or DRG explants under high-glucose conditions. We found that Lipocalin 2 (Lcn2) is a new target of PC-NVs in this process, indicating that PC-NVs exert their angiogenesis and nerve regeneration effects by activating MAP kinase, PI3K/Akt and suppressing P53 signaling pathway in an Lcn2-dependent manner under diabetic conditions. Our findings provide new conclusive evidence that PC-NVs mediate neurovascular regeneration and erectile function recovery under diabetic conditions through an Lcn2-dependent mechanism. Local administration of PC-NVs may be a promising treatment strategy for the treatment of diabetic ED.

2022-07-13 | GSE183220 | GEO

Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma

Project description:This randomized phase I/II clinical trial is studying the side effects and best dose of gamma-secretase/notch signalling pathway inhibitor RO4929097 when given together with vismodegib and to see how well they work in treating patients with advanced or metastatic sarcoma. Vismodegib may slow the growth of tumor cells. Gamma-secretase/notch signalling pathway inhibitor RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving vismodegib together with gamma-secretase/notch signalling pathway inhibitor RO4929097 may be an effective treatment for sarcoma.

| 2091475 | ecrin-mdr-crc

H3K27ac Hi-ChIP analysis in Jurkat and RPMI-8402 T-ALL cells

Project description:H3K27ac Hi-ChIP analysis was performed in Jurkat and RPMI-8402 stably expressing dCAR9-KRAB after treatment with DMSO (Control) or Doxycycline to induce sgRNA expression to block MYCN enhnacer region

2023-08-16 | GSE231957 | GEO

RNA-seq analysis in RPMI-8402 cells after knockout of MYC and MYCN

Project description:RNA-seq analysis was performed in a RPMI-8402 T-ALL cell stably expressing Cas9 aafter knockout of both MYC and MYCN

2023-08-16 | GSE231962 | GEO